Article
Life-threatening Pneumonitis Induced by Osimertinib Monotherapy as a First-line Treatment for Epidermal Growth Factor Receptor Mutation-positive Non-small-cell Lung Cancer: A Retrospective Case-series Study.
Anticancer research - 1 May 2026
Nojiri Takashi, Omura Akiisa, Nishimura Hiroshi, Uda Hiroshi, Katayama Michihito, Iede Kiyotsugu, Takeyasu Yuki, Katsushima Utae, Okada Hiroshi, Higashiyama Masahiko
Abstract excerpt
BACKGROUND/AIM: Drug-related pneumonitis is a recognized adverse event associated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small-cell lung cancer (NSCLC). Osimertinib, a third-generation EGFR-TKI, has demonstrated favorable efficacy and safety as a first-line therapy for advanced EGFR-mutated NSCLC. However, osimertinib-induced pneumonitis can be fatal, and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.